KIDS vs. NVCR, LMAT, EYE, ENOV, CNMD, TNDM, SSII, CDRE, AORT, and LQDA
Should you be buying OrthoPediatrics stock or one of its competitors? The main competitors of OrthoPediatrics include NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Tandem Diabetes Care (TNDM), SS Innovations International (SSII), Cadre (CDRE), Artivion (AORT), and Liquidia Technologies (LQDA). These companies are all part of the "medical equipment" industry.
OrthoPediatrics vs. Its Competitors
NovoCure (NASDAQ:NVCR) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.
OrthoPediatrics has lower revenue, but higher earnings than NovoCure. OrthoPediatrics is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.
OrthoPediatrics has a net margin of -19.15% compared to NovoCure's net margin of -26.41%. OrthoPediatrics' return on equity of -7.03% beat NovoCure's return on equity.
In the previous week, NovoCure had 6 more articles in the media than OrthoPediatrics. MarketBeat recorded 10 mentions for NovoCure and 4 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.40 beat NovoCure's score of 0.39 indicating that OrthoPediatrics is being referred to more favorably in the news media.
84.6% of NovoCure shares are owned by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are owned by institutional investors. 5.5% of NovoCure shares are owned by insiders. Comparatively, 32.7% of OrthoPediatrics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
NovoCure has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.
NovoCure currently has a consensus target price of $32.83, suggesting a potential upside of 85.45%. OrthoPediatrics has a consensus target price of $35.83, suggesting a potential upside of 59.51%. Given NovoCure's higher possible upside, equities analysts plainly believe NovoCure is more favorable than OrthoPediatrics.
Summary
OrthoPediatrics beats NovoCure on 9 of the 16 factors compared between the two stocks.
Get OrthoPediatrics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KIDS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KIDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OrthoPediatrics Competitors List
Related Companies and Tools
This page (NASDAQ:KIDS) was last updated on 7/3/2025 by MarketBeat.com Staff
Free KIDS Stock Alerts